← Back to Patent Explorer
US4031222A Expired / Lapsed US ⏱️ 0.0 years remaining

Trifluoromethylthio (and sulfonyl) derivatives of cyproheptadine analogs

Assignee: Merck and Co Inc
•
Filing: 1975-12-22
•
Granted: 1977-06-21
•
Expires: 1995-12-22
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Cyproheptadine derivatives substituted with a trifluoromethylthio or trifluoromethylsulfonyl group in one of the benzo rings and having a hydroxyalkyl or cycloalkylalkyl group on the piperidine nitrogen are potent antipsychotic agents, with a low propensity to induce extrapyramidal side effects that are experienced with most major tranquilizers. The tranquilizing activity is predominantly in the levorotatory enantiomers, whereas the dextrorotatory enantiomers have anticholinergic activity. Each enantiomer is useful as a source of the other by racemization. The novel compounds are prepared by treatment of the corresponding iodo or bromo compound with bis(trifluoromethylthio)mercury and copper powder.

Inventors

  • 👤 David C. Remy

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 00:11
CPC Classifications
C; C07; C07D; C07D211/00; C07D211/04; C07D211/06; C07D211/36; C07D211/38; A; A61; A61P; A61P25/00; A61P25/18; C07D211/40; C07D211/44; C07D211/68; C07D211/70; C07D211/72; C07D211/74; C07D211/76; C07F; C07F3/00; C07F3/02

Claims Analysis

Total Claims: 19
Claim 1
Independent Claim 38 words
A compound of structural formula: ##STR10## or a pharmaceutically acceptable salt thereof, wherein R 1 is --SCF 3 or SO 2 CF 3 , R 2 is ##STR11## and R 3 is hydrogen, C 1-3 alkyl or fluoro.
Claim 2
Dependent Claim 38 words
A compound of structural formula: ##STR10## or a pharmaceutically acceptable salt thereof, wherein R 1 is --SCF 3 or SO 2 CF 3 , R 2 is ##STR11## and R 3 is hydrogen, C 1-3 alkyl or fluoro.
Claim 3
Dependent Claim 14 words
The compound of claim 1 of structural formula: ##STR12## or pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim 15 words
The compound of claim 2 or pharmaceutically acceptable salt thereof wherein R 3 is hydrogen.
Claim 5
Dependent Claim 17 words
The compound of claim 3 or pharmaceutically acceptable salt thereof wherein R 1 is --SCF 3 .
Claim 6
Dependent Claim 19 words
The compound of claim 3 or pharmaceutically acceptable salt thereof wherein R 1 is --SO 2 CF 3 .
Claim 7
Dependent Claim 13 words
The compound of claim 4, which is 1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine, or pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim 17 words
The levorotatory enantiomer of the compound of claim 6 which is (-)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine, or pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim 17 words
The dextrorotatory enantiomer of the compound of claim 6, which is (±)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine, or pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim 25 words
A levorotatory enantiomer of the compound of structural formula: ##STR13## wherein R 2 is ##STR14## and R 3 is hydrogen, C 1-3 alkyl or fluoro.
Claim 11
Dependent Claim 25 words
A levorotatory enantiomer of the compound of structural formula: ##STR13## wherein R 2 is ##STR14## and R 3 is hydrogen, C 1-3 alkyl or fluoro.
Claim 12
Dependent Claim 13 words
The levorotatory enantiomer of the compound of claim 9 of structural formula: ##STR15##
Claim 13
Independent Claim 58 words
A method of treating psychoses which comprises the administration to a patient in need of such treatment an effective amount of a compound of structural formula: ##STR16## or pharmaceutically acceptable salt thereof, wherein R 1 is --SCF 3 or SO 2 CF 3 ; R 2 is ##STR17## and R 3 is hydrogen, C 1-3 alkyl or fluoro.
Claim 14
Independent Claim 58 words
A method of treating psychoses which comprises the administration to a patient in need of such treatment an effective amount of a compound of structural formula: ##STR16## or pharmaceutically acceptable salt thereof, wherein R 1 is --SCF 3 or SO 2 CF 3 ; R 2 is ##STR17## and R 3 is hydrogen, C 1-3 alkyl or fluoro.
Claim 15
Dependent Claim 24 words
The method of claim 11 wherein the compound is the levorotatory enantiomer of the compound of structural formula: ##STR18## or pharmaceutically acceptable salt thereof.
Claim 16
Dependent Claim 58 words
A pharmaceutical composition in unit dosage form for the treatment of psychoses comprising a carrier and an effective amount of a compound of structural formula: ##STR19## or a pharmaceutically acceptable salt thereof, wherein R 1 is --SCF 3 or SO 2 CF 3 , R 2 is ##STR20## and R 3 is hydrogen, C 1-3 alkyl or fluoro.
Claim 17
Dependent Claim 58 words
A pharmaceutical composition in unit dosage form for the treatment of psychoses comprising a carrier and an effective amount of a compound of structural formula: ##STR19## or a pharmaceutically acceptable salt thereof, wherein R 1 is --SCF 3 or SO 2 CF 3 , R 2 is ##STR20## and R 3 is hydrogen, C 1-3 alkyl or fluoro.
Claim 18
Dependent Claim 25 words
The pharmaceutical composition of claim 13, wherein the compound is the levorotatory enantiomer of the compound of structural formula: ##STR21## or pharmaceutically acceptable salt thereof.
Claim 19
Dependent Claim 13 words
The dextrorotatory enantiomer of the compound of claim 9 of structural formula: ##STR22##

References Cited (Backward Citations)

US3851059A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-06-20 1980-12-20 1981-06-21 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-06-20 1984-12-20 1985-06-21 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-06-20 1988-12-20 1989-06-21 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag